Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Opa-Locka, Florida Clinical Trials

A listing of Opa-Locka, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (257) clinical trials

Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

The investigational medicinal product (IMP) IMU-838 (vidofludimus calcium) is a new compound that selectively inhibits the human enzyme dihydroorotate dehydrogenase (DHODH). Dihydroorotate dehydrogenase plays a major role in the de-novo pyrimidine synthesis and is specifically expressed at high levels in proliferating or activated lymphocytes. Resting lymphocytes satisfy their pyrimidine requirements ...

Phase

3.08 miles

Learn More »

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

This is a randomized, placebo-controlled, double-blind phase 2 trial evaluating approximately 76 subjects with symptomatic AERD on the safety and efficacy of 8 weeks of oral ifetroban treatment. Eligible AERD subjects will be randomized to receive 8 weeks of either oral ifetroban daily or matching placebo followed by a 2-week ...

Phase

3.27 miles

Learn More »

Efficacy and Safety of TD-1473 in Crohn's Disease

A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 12 weeks of induction therapy with TD1473 in subjects with moderately-to-severely active CD. This study includes 3 phases: Screening, Induction, and Active Treatment Extension (ATE). The Induction phase of the study is a ...

Phase

3.27 miles

Learn More »

Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis

The primary objective of this study is to assess the efficacy and safety of two doses of vilaprisan compared to placebo in women with symptomatic endometriosis. The secondary objective of this study is to evaluate the safety and tolerability of two different doses of vilaprisan in women with symptomatic endometriosis.

Phase

3.27 miles

Learn More »

This phase 2 study is a multicenter, exploratory study designed to evaluate the efficiency and safety of Febuxostat 40 mg in subjects with Gout and moderate renal impairment.

Phase

3.27 miles

Learn More »

RSV Investigational Vaccine in RSV-seropositive Infants Aged 12 to 23 Months

The RSV PED-002 study, designed to evaluate the safety, reactogenicity and immunogenicity of the RSV candidate vaccine when administered in 3 sequential doses to seropositive infants aged 12 to 23 months, will be conducted in an observer-blind manner in Epoch 1 and single-blinded in Epoch 2.

Phase

3.43 miles

Learn More »

Study of Efficacy Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy

This is a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c. secukinumab 300 mg in approximately 100 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease. The study consists of a 4-week screening period, a 2-week run-in period, a 12-week treatment period and a 12-week follow-up period after ...

Phase

3.43 miles

Learn More »

Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects

This clinical trial is a phase 2, double-blind dose escalation regimen of once-weekly OPK-88003 in subjects with T2DM. The trial consists of four phases: a screening/baseline phase (up to 2 weeks prior to first dose), a 30-week treatment period consisting of a dose escalation phase (8 weeks) and a target ...

Phase

3.43 miles

Learn More »

Study to Assess the Safety Tolerability Efficacy and PK of APL-2 in Patients With wAIHA or CAD

This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).

Phase

3.5 miles

Learn More »

Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

The primary purpose of the study is to evaluate the efficacy of BIIB059 in reducing disease activity in participants with systemic lupus erythematosus (SLE) with active cutaneous manifestations and joint involvement (Part A), and in participants with active cutaneous lupus erythematosus (CLE) (Subacute cutaneous lupus erythematosus (SCLE) or chronic CLE, ...

Phase

3.5 miles

Learn More »